Lv1
70 积分 2025-11-24 加入
DOP049 Vedolizumab is more effective at inducing histo-endoscopic healing in early Crohn’s Disease compared to late CD, with comparable healing rates regardless of disease location: data from the LOVE-CD trial
2小时前
求助中
Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences
10个月前
已完结
P0517 Role of radiomics in predicting the degree of intestinal fibrosis in patients with Crohn’s Disease
10个月前
已完结
Histone lactylation: A key epigenetic modulator in the pathogenesis of metabolic dysfunction-associated steatohepatitis and alcoholic steatohepatitis
10个月前
已完结
[A Case of Synchronous Double Colitic Cancer in Crohn's Disease]
11个月前
已关闭
P006 Development of a Crohn's disease molecular activity score to identify region-specific chronically inflamed and non-inflamed processes
11个月前
已关闭
FoxP3-positive T regulatory cells and its effector mechanisms in Crohn’s disease: an immunohistochemical and image morphometric analysis on endoscopic mucosal biopsies
11个月前
已完结
P247 Oncostatin M and its receptor are markers of endoscopic and histological disease activity in Inflammatory Bowel Disease
11个月前
已关闭
Combined endoscopic and histological healing with vedolizumab in therapy-refractory Crohn's disease, data from the LOVE -CD trial
11个月前
已关闭
皖公网安备34019202002308
